Impact of sibutramine (meridia) on body composition, peptide YY3-36 and serotonin levels in patients with exogenous constitutional obesity


如何引用文章

全文:

详细

Aim. To evaluate the impact of gradual weight loss and the positive effect of sibutramine on metabolic parameters and the levels of serotonin and neuropeptide YY3-36 levels in patients with exogenous constitutional obesity (ECO).
Subjects and methods. The study included 36 patients (24 women and 12 men; mean age 37.56±0.9 years) with a verified diagnosis of ECO. The height, body weight, waist and hip circumference (WC and HC), and body mass index (BMI) were determined. Adipose tissue content was estimated by a bioimpedance method using an adipose mass analyzer. Serum peptide YY3-36 levels were measured by enzyme immunoassay and blood serotonin concentrations were estimated by high performance liquid chromatography with an electrochemical method.
Results. 12-week sibutramine therapy caused a significant reduction in body weight, WC, HC, and BMI (p < 0.05) in all the patients. At the same time they were found to have a considerable body composition change (total body and visceral fat was decreased, total body water increased, and systemic metabolism was lowered). The mean peptide YY3-36 level was significantly decreased. Sibutramine did not affect the serum content of total serotonin in the sera of patients.
Conclusion. Sibutramine used in the combined therapy in patients with ECO contributes to an effective and steady-state weight loss. Sibutramine treatment causes a reduction in total neuropeptide YY3-36, systemic metabolism, and adipose tissue at the expense of the visceral depot.

作者简介

Yu Vlasova

Russian Medical Academy of Postgraduate Education, Federal Agency for Health Care and Social Development

Email: novorappid@mail.ru
кафедра эндокринологии и диабетологии с курсом эндокринной хирургииканд. мед. наук, докторант; Федеральное агентство по здравоохранению и социальному развитию Государственное образовательное учреждение дополнительного профессионального образования Российская медицинская академия последипломного образования; Russian Medical Academy of Postgraduate Education, Federal Agency for Health Care and Social Development

A Ametov

Russian Medical Academy of Postgraduate Education, Federal Agency for Health Care and Social Development

Email: Alexander.ametov@gmail.com
кафедра эндокринологии и диабетологии с курсом эндокринной хирургиир мед. наук, проф., зав. каф; Федеральное агентство по здравоохранению и социальному развитию Государственное образовательное учреждение дополнительного профессионального образования Российская медицинская академия последипломного образования; Russian Medical Academy of Postgraduate Education, Federal Agency for Health Care and Social Development

参考

  1. Schwartz M. W., Wood S. C., Porte D. Jr. et al. Central nervous system control of food intake. Nature 2000; 404: 661- 671.
  2. Konturek P. C., Czenikiewicz-Guzik M., Bielanski W. et al. Neuro-hormonal control of food intake; basic mechanisms and clinical implications. J. Physiol. Pharmacol. 2005; 6: 5-25.
  3. Sahu A. Minireview: A hypothalamic role in energy balance with special emphasis on leptin. Endocrinology 2004; 145 (6): 2613-2620.
  4. Пигарева Е. А., Дзеранова Л. К., Рожинская Л. Я. и др. Ожирение и гинекомастия у пациента с центральным несахарным диабетом. Ожирение и метаболизм 2006; 8: 51- 54.
  5. Schwartz. M. W. Specificity of leptin action on elevated blood glucose levels and hypothalamic neuropeptide Y gene expression in ob/ob mice. Diabetes 1996; 45: 531-535.
  6. Nonogaki K., Strack A., Dallman M. et al. Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT2C receptor gene. Nat. Med. 1998; 4: 1152-1156.
  7. Calapai G. Leptin increases serotonin turnover by inhibition of brain nitric oxide synthesis. J. Clin. Invest. 1999; 104: 975- 982.
  8. Пальцев М. А., Кветной И. М. Руководство по нейроиммунологии. М.: Медицина; 2006.
  9. Viardot A., Heilbronn L. K., Herzog H. et al. Abnormal postprandial PYY response in insulin sensitive nondiabetic subject with a strong family history of type 2 diabetes. Int. J. Obes. 2008; 32: 943-948.
  10. Бутрова С. А. Сибутрамин (меридиа) в лечении ожирения: опыт применения в России. Клин. фармакол. и тер. 2001 10 (2): 70-75.
  11. Сметник В. П., Чернуха Г. Е., Валуева Л. Г. Применение сибутрамина (меридиа) у больных с ожирением и нарушением функции яичников. Пробл. репрод. 2002; 1: 10-15.
  12. Finer N. Does pharmacologically induced weight loss improve cardiovascular outcome? Impact of anti-obesity agents on cardiovascular risk factors. J. Eur. Heart 2005; 7: 32-38.
  13. Hainer V., Kabrnova K., Aldhoon B. et al. Serotonin and norepinephrine reuptake inhibition and eating behavior. Ann. N. Y. Acad. Sci. 2006; 1083 (1): 252-269.
  14. Luquy C. A., Rey J. A. The discovery and status of sibutramine as an anti-obesity drug. Eur. J. Pharmacol. 2002; 440: 119- 128.
  15. Phelan S., Wadden T. F. Combining behavior and pharmacological treatments for obesity. Obesity 2002; 10 (6): 560-574.
  16. Bray G. A., Blackburn G. L., Ferguson J. M. et al. Sibutramine produces dose-related weight loss. Obes. Res. 1999; 7: 189- 198.
  17. Bray G., Ryan D., Gordon D. et al. A double-blind randomized placebo-contolled trial of sibutramine. Obes. Res.. 1996; 4 (3): 263-270.
  18. Wood S. C., Seeley R. J. Understanding the physiology of obesity: review of recent developments in obesity research. Int. J. Obes. Relat. Metab. 2002; 26: 8-10.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Consilium Medicum, 2010

Creative Commons License
此作品已接受知识共享署名-非商业性使用-相同方式共享 4.0国际许可协议的许可。
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


##common.cookie##